Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in extremely preterm infants
ACTRN12611000145909Phase 2Not yet recruiting
- Sponsor
- King Edward Memorial Hospital
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pentoxifylline in bronchopulmonary dysplasia (BPD), sponsored by King Edward Memorial Hospital. Primary endpoint: Duration on supplemental oxygen. Planned start Mar 2011; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on ACTRN12611000145909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000145909.